Zeynep Erdogan Iyigun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zeynep Erdogan Iyigun has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Alper Ozturk
Biruni Univ, Fac Med, Dept Gen Surg, Istanbul, Turkiye
4 shared publications - Cetin Ordu
Department of Medical Oncology, Gayrettepe Florence Nightingale Hospital, Istanbul, Turkey
4 shared publications - Gul Alco
Department of Radiation Oncology, Gayrettepe Florence Nightingale Hospital, Istanbul, Turkey
4 shared publications - Ahmet Serkan Ilgun
Specialist Breast and General Surgeon, Department of General and Vascular Surgery, Mater Dei Hospital, St. Paul’s Bay, Malta
3 shared publications - Fatma Aktepe
Department of Pathology, Gayrettepe Florence Nightingale Hospital, Istanbul, Turkey
3 shared publications - Filiz Çelebi
Yeditepe Univ, Fac Med, Dept Radiol, Istanbul, Turkiye
3 shared publications
Latest Publications
- Open Access
- 2 January 2025
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 21 (1) , 40-45
Evaluation of Long-Term Lymphedema Rate in Patients With Subclinical Lymphedema Diagnosed in the Preoperative Period via Bioimpedance
Undefined - European Journal of Breast Health
- 2 January 2025
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 21 (1) , 40-45
Open AccessEvaluation of Long-Term Lymphedema Rate in Patients With Subclinical Lymphedema Diagnosed in the Preoperative Period via Bioimpedance
Undefined - European Journal of Breast Health
- 26 August 2022
- Published by Taylor & Francis in Future Oncology
- Vol. 18 (29) , 3289-3298
The effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes in patients with breast cancer
Aim: This study investigated the effect of neoadjuvant chemotherapy (NAC) on stromal tumor-infiltrating lymphocytes (sTILs) and their treatment response. Materials & methods: One hundred fifteen pa... Plain language summary New studies have shown that the tumor microenvironment is critical in tumor behavior. Immune cells surrounding tumor cells are the main components of the tumor microenvironme...
- 26 August 2022
- Published by Taylor & Francis in Future Oncology
- Vol. 18 (29) , 3289-3298
The effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes in patients with breast cancer
Aim: This study investigated the effect of neoadjuvant chemotherapy (NAC) on stromal tumor-infiltrating lymphocytes (sTILs) and their treatment response. Materials & methods: One hundred fifteen pa... Plain language summary New studies have shown that the tumor microenvironment is critical in tumor behavior. Immune cells surrounding tumor cells are the main components of the tumor microenvironme...
- 24 June 2020
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 16 (3) , 177-182
The Effect of Systemic Chemotherapy on Ovarian Function: A Prospective Clinical Trial
AMH,ovarian reserve,breast cancer,chemotherapy
- 24 June 2020
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 16 (3) , 177-182
The Effect of Systemic Chemotherapy on Ovarian Function: A Prospective Clinical Trial
AMH,ovarian reserve,breast cancer,chemotherapy
- 29 June 2018
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 14 (3) , 173-179
Prognostic Significance of Adjuvant Chemotherapy Induced Amenorrhea in Luminal A and B Subtypes
Objective: In this retrospective study, chemotherapy induced amenorrhea in patients with early stage breast cancer and its effects on survival were investigated. Materials and Methods: Two hundred fifty-two patients received adjuvant chemotherapy without ovarian suppression treatment (OST) from 600 premenopausal patients were included in the study. Patients were divided into two groups; with amenorrhea and without, and compared with clinicopathologic features and survival. SPSS version 17 was used. Results: Chemotherapy-induced amenorrhea (CIA) was observed in 145 (57.5%) of 252 patients who received no OST during follow-up. The 5-year OS rate of patients with CIA was significantly higher than patients without CIA (p=0.042, 95.9% vs. 89.7% vs. 158.88 vs. 135.33 months, respectively). In the subgroup analysis, the OS in patients with hormone receptor (+) was significantly higher than in those receptor (-) in patients with CIA (p=0.011, 97.5% vs. 90.9% vs. 162.13 vs. 126.16 months, respectively). The OS was significantly longer in the luminal A molecular subtype than in those with luminal B molecular subtype, in patients with CIA, but the difference was not significant in patients without CIA (p=0.027 vs. p=0.074, respectively).** Conclusion: As a conclusion; survival advantage of the chemotherapy induced amenorrhea more pronounced with hormone receptor positivity, lymph node involvement, and advanced disease over patients who do not develop amenorrhea. This advantage of amenorrhea development further prolongs survival compared with luminal B in the luminal A molecular subtype.
- 29 June 2018
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 14 (3) , 173-179
Prognostic Significance of Adjuvant Chemotherapy Induced Amenorrhea in Luminal A and B Subtypes
Objective: In this retrospective study, chemotherapy induced amenorrhea in patients with early stage breast cancer and its effects on survival were investigated. Materials and Methods: Two hundred fifty-two patients received adjuvant chemotherapy without ovarian suppression treatment (OST) from 600 premenopausal patients were included in the study. Patients were divided into two groups; with amenorrhea and without, and compared with clinicopathologic features and survival. SPSS version 17 was used. Results: Chemotherapy-induced amenorrhea (CIA) was observed in 145 (57.5%) of 252 patients who received no OST during follow-up. The 5-year OS rate of patients with CIA was significantly higher than patients without CIA (p=0.042, 95.9% vs. 89.7% vs. 158.88 vs. 135.33 months, respectively). In the subgroup analysis, the OS in patients with hormone receptor (+) was significantly higher than in those receptor (-) in patients with CIA (p=0.011, 97.5% vs. 90.9% vs. 162.13 vs. 126.16 months, respectively). The OS was significantly longer in the luminal A molecular subtype than in those with luminal B molecular subtype, in patients with CIA, but the difference was not significant in patients without CIA (p=0.027 vs. p=0.074, respectively).** Conclusion: As a conclusion; survival advantage of the chemotherapy induced amenorrhea more pronounced with hormone receptor positivity, lymph node involvement, and advanced disease over patients who do not develop amenorrhea. This advantage of amenorrhea development further prolongs survival compared with luminal B in the luminal A molecular subtype.
- 1 February 2018
- Published by SAGE Publications in Lymphatic Research and Biology
- Vol. 16 (1) , 28-35
Preoperative Lymphedema-Related Risk Factors in Early-Stage Breast Cancer
Background: Prolongation of survival in patients with breast cancer due to early diagnosis and modern methods of treatment has turned the attention on lymphedema, which is the most important morbidity secondary to the treatment of the disease. Determination of lymphedema and related risk factors in patients before a surgical intervention may provide protection for patients and early treatment. The aim of this study was to determine the presence of lymphedema before surgery by bioimpedance analysis in patients with breast cancer and to establish risk factors associated with lymphedema. Patients and Methods: A total of 277 patients who were diagnosed as having breast cancer, were planned to undergo a surgical intervention, and had no clinical lymphedema were included in the study. The presence of lymphedema was evaluated with clinical examination, measurement of arm circumference, and bioimpedance analysis. Results: Lymphedema was found in 59 (21.3%) patients with no detected differences in arm circumferences. A significant relationship was found between the presence of lymphedema and body mass index (BMI), number of positive lymph nodes, and capsule invasion of the tumor (p = 0.001, p = 0.003, p = 0.002, respectively). Multiple regression analysis revealed that BMI and the number of positive lymph nodes were independent variables (p = 0.024, p = 0.002). ROC curve analysis resulted in an increased risk of preoperative lymphedema when the number of positive lymph nodes was ≥8. Correlation analysis revealed a positive correlation between the number of positive lymph nodes and L-dex score (p = 0.001, r = 0.219). Conclusion: Preoperative bioimpedance analysis demonstrated that ∼1/5 of the patients had subclinical lymphedema. Preoperative subclinical lymphedema is associated with obesity and the number of positive lymph nodes, and thus, treatment of the axilla in patients who are preoperatively detected to have subclinical lymphedema should be revised.
- 1 February 2018
- Published by SAGE Publications in Lymphatic Research and Biology
- Vol. 16 (1) , 28-35
Preoperative Lymphedema-Related Risk Factors in Early-Stage Breast Cancer
Background: Prolongation of survival in patients with breast cancer due to early diagnosis and modern methods of treatment has turned the attention on lymphedema, which is the most important morbidity secondary to the treatment of the disease. Determination of lymphedema and related risk factors in patients before a surgical intervention may provide protection for patients and early treatment. The aim of this study was to determine the presence of lymphedema before surgery by bioimpedance analysis in patients with breast cancer and to establish risk factors associated with lymphedema. Patients and Methods: A total of 277 patients who were diagnosed as having breast cancer, were planned to undergo a surgical intervention, and had no clinical lymphedema were included in the study. The presence of lymphedema was evaluated with clinical examination, measurement of arm circumference, and bioimpedance analysis. Results: Lymphedema was found in 59 (21.3%) patients with no detected differences in arm circumferences. A significant relationship was found between the presence of lymphedema and body mass index (BMI), number of positive lymph nodes, and capsule invasion of the tumor (p = 0.001, p = 0.003, p = 0.002, respectively). Multiple regression analysis revealed that BMI and the number of positive lymph nodes were independent variables (p = 0.024, p = 0.002). ROC curve analysis resulted in an increased risk of preoperative lymphedema when the number of positive lymph nodes was ≥8. Correlation analysis revealed a positive correlation between the number of positive lymph nodes and L-dex score (p = 0.001, r = 0.219). Conclusion: Preoperative bioimpedance analysis demonstrated that ∼1/5 of the patients had subclinical lymphedema. Preoperative subclinical lymphedema is associated with obesity and the number of positive lymph nodes, and thus, treatment of the axilla in patients who are preoperatively detected to have subclinical lymphedema should be revised.